% | $
Quotes you view appear here for quick access.

ImmunoGen, Inc. Message Board

  • gappertrade gappertrade Feb 25, 2013 8:44 AM Flag

    Price target raised to $21.00 from $17.00 by Jefferies, what is it that you idiot sellers don't understand

    What is it that you moronic pre market sellers just don't seem to grasp in your small brains.

    Sentiment: Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • UPDATE: Jefferies Reiterates Buy Rating, Raises PT on ImmunoGen on Kadcyla Approval
      10:35a ET February 25, 2013 (Benzinga) In a report published Monday, Jefferies reiterated its Buy rating on ImmunoGen (NASDAQ: IMGN), and raised its price target from $17.00 to $21.00.

      Jefferies noted, “IMGN and partner Roche announced that Kadcyla (T-DM1) has been approved and priced at $9,800 per month. Kadcyla pricing is 33% higher than we had expected, and as a result, we are raising our IMGN PT from $17 to $21.”

    • I have to say, I was not a big fan of Thomas when he was against ARNA, but he was right the first time ARNA was rejected, then later he came around on them, long story short, I am warming up to him as an analyst, he's actually pretty good and I rarely say that. Maybe IMGN will make another run at $15 today.

      Just be glad you don't own AFFY today...a reminder the risk of biotech is substantial. I owned it from about $5-6 and sold at $13-15 and watched it go into the $20's. Had been thinking it was becoming a good value again lately, but was afraid of the falling knife chart pattern.

2.82-0.05(-1.74%)Sep 23 4:00 PMEDT